

Axinn Secures IPR Victory for Par in Challenge to Horizon's Ravicti Patent

NEWS | 1 MIN READ

September 29, 2016

On behalf of Par Pharmaceutical, Inc., attorneys from Axinn successfully challenged U.S. Patent No. 8,404,215 via an *inter partes* review (IPR) before the Patent Trials and Appeals Board (PTAB) at the United States Patent and Trademark Office. The '215 patent is listed in FDA's Orange Book for Ravicti (glycerol phenylbutyrate), a brand name drug used to treat urea cycle disorders. On July 26, 2016, the PTAB heard oral argument on the validity of the '215 patent, and on September 29, 2016 the PTAB issued a Final Decision finding all claims unpatentable.

The company that markets Ravicti and owns the '215 patent, Horizon Therapeutics, Inc., had previously asserted the '215 patent against Par in the United States District Court for the Eastern District of Texas. In a separate action in the United States District Court for the District of New Jersey, Horizon has also asserted against Par three closely-related patents in the same family as the unpatentable '215 patent, which claim nearly identical subject matter.

The Axinn team representing Par in the '215 patent IPR consisted of Aziz Burgy and Matthew Murphy.

Related People



Aziz Burgy



Matthew S. Murphy

To subscribe to our publications, [click here](#).

Featured Insights

- Consumer Brands CPG Legal Forum 2026
SPEAKING ENGAGEMENT
- NBA CLS 39th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
SPEAKING ENGAGEMENT ANTITRUST
- GCR Live Global: Navigating the Future of Antitrust 2026
SPEAKING ENGAGEMENT ANTITRUST
- Why Should I Care About Property Controls?
SPEAKING ENGAGEMENT ANTITRUST
- What's the Score, Your Honor? Conversation With Judge Richard Boulware
PODCAST
- LCA Renaissance Symposium XIX 2025
SPEAKING ENGAGEMENT ANTITRUST
- Stakeholders 25th Annual CYOC Career Development Conference
SPONSORSHIP ANTITRUST

- Japan Competition Law Update

AXINN VIEWPOINTS ANTITRUST

- California's Crackdown on Algorithmic Pricing

AXINN VIEWPOINTS ANTITRUST

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved